[{"id":"74935b5a-a7e9-4357-95ea-10d54e3b1962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04237805","created_at":"2021-01-17T17:53:59.682Z","updated_at":"2024-07-02T16:36:28.174Z","phase":"Phase 1/2","brief_title":"A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients","source_id_and_acronym":"NCT04237805","lead_sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK positive • ROS1 positive","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e foritinib (SAF-189)"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 11/14/2016","start_date":" 11/14/2016","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2021-07-08"}]